Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

por Muñoz, Delicias, Escartín, Antonio, Dapena, Dolores, Coret, Francisco, Fernández-Uría, Dionisio, Pérez, Domingo, Casanova, Bonaventura, Guijarro-Castro, Cristina, Munteis, Elvira, del-Campo Amigo, María, Pego, Robustiano, Calles, Carmen, García-Rey, César, Monsalve, Nuria, Sánchez-Matienzo, David
Publicado 2013

Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach

por Sainz de la Maza, Susana, Gómez-Ballesteros, Rocío, Borges, Mónica, Martín-Martínez, Jesús, Sotoca, Javier, Alonso, Ana, Caminero, Ana B, Borrega, Laura, Sánchez-Menoyo, José L, Barrero-Hernández, Francisco J, Calles, Carmen, Brieva, Luis, Blasco-Quílez, María R, Dotor García-Soto, Julio, del Campo-Amigo, María, Navarro-Cantó, Laura, Agüera, Eduardo, Garcés-Redondo, Moisés, Carmona, Olga, Gabaldón-Torres, Laura, Forero, Lucía, Hervàs, Mariona, Medrano, Nicolás, Maurino, Jorge, Castillo-Triviño, Tamara
Publicado 2023